Loading clinical trials...
Loading clinical trials...
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions
Interventions
MEDI4736
MEDI4736 + Tremelimumab
+1 more
Locations
168
United States
Research Site
Tucson, Arizona, United States
Research Site
Fullerton, California, United States
Research Site
Los Angeles, California, United States
Research Site
Redondo Beach, California, United States
Research Site
Stanford, California, United States
Research Site
Denver, Colorado, United States
Start Date
September 9, 2015
Primary Completion Date
September 10, 2018
Completion Date
November 13, 2020
Last Updated
February 10, 2021
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions